MDM2 and mesothelioma: Cotargeting of FAK-p53 and MDM2-p53 interactions exhibited antiproliferative effects in mesothelioma [24], suggesting that p53 functional inactivation is a key event in mesothelioma development, as genomic TP53 mutations are not frequent in mesothelioma [29].